







A**B****C**

Additional file 11: Figure S8. ADU-1805 is devoid of immune effector functions exemplified in complement and FcγR-dependent assays.

(A) ADU-1805 does not engage FcγRIIA-131H. A human IgG1 variant of the chimeric KWAR23 antibody (KWAR23.C1; red line) represents a positive IgG1 antibody control that engages FcγRIIA-131H on Jurkat cells. **(B)** ADU-1805 does not trigger NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). A human IgG1 variant of the chimeric hSIRPα.40A antibody (hSIRPα.40.C1; red line) represents a positive IgG1 antibody control that induces ADCC. **(C)** ADU-1805 lacks complement-dependent cytotoxicity (CDC) activity. The anti-MHC-1 antibody (red line) represents a positive human IgG1 antibody control that induces CDC. MAC, membrane attack complex. (A, B, C: Mean ± SD; representative of $n = 2$ is shown).